公开(公告)号：US20250066486A1

公开(公告)日：2025-02-27

申请号：US18825514

申请日：2024-09-05

Applicant: Orionis Biosciences Inc. ,  Orionis Biosciences BV

Inventor： Nikolai KLEY ,  Jan TAVERNIER ,  Lennart ZABEAU ,  Erik DEPLA

IPC: C07K16/28 ,  A61K38/17 ,  A61K38/21 ,  A61K39/395 ,  A61K39/40 ,  A61K39/42 ,  A61P25/00 ,  C07K14/47 ,  C07K16/00 ,  C07K16/18

Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.

公开(公告)号：US12194157B2

公开(公告)日：2025-01-14

申请号：US18544302

申请日：2023-12-18

Applicant: Finncure Oy

Inventor： Erik Johan Niemelä

IPC: A61K39/00 ,  A61K9/00 ,  A61K9/16 ,  A61K9/50 ,  A61K9/51 ,  A61K31/56 ,  A61K31/7105 ,  A61K31/711 ,  A61K33/30 ,  A61K39/145 ,  A61K39/215 ,  A61K39/42 ,  A61K47/62 ,  A61K47/69 ,  C07K14/08 ,  C07K17/00 ,  C07K17/02 ,  C07K17/14

Abstract: According to some embodiments, a method of providing treatment of a host comprises binding a carrier to cell structures of cells of the host to reduce a likelihood of an agent binding to said cell structures to at least partially inhibits the agent from binding to said cell structures, wherein the carrier comprises a core and a surface functionalized on the core, wherein the functionalized surface bind to target areas of cell structures of the host's cells, and wherein the carrier is to be used as targeted treatment for one or more disease, infections or allergic reactions caused by a disease-causing agent or source.

公开(公告)号：US20240425569A1

公开(公告)日：2024-12-26

申请号：US18752260

申请日：2024-06-24

Applicant: VISTERRA, INC.

Inventor： Luke Robinson ,  Zachary Shriver ,  James R. Myette ,  Gregory Babcock ,  Karthik Viswanathan

IPC: C07K16/10 ,  A61K39/00 ,  A61K39/42 ,  A61K45/06 ,  G01N33/569

Abstract: Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.

公开(公告)号：US12157763B2

公开(公告)日：2024-12-03

申请号：US18403419

申请日：2024-01-03

Applicant: ACADEMIA SINICA

Inventor： Kuo-I Lin ,  Che Ma ,  Chi-Huey Wong ,  Szu-Wen Wang ,  Yi-Hsuan Chang ,  Xiaorui Chen ,  Han-Yi Huang

IPC: C07K16/10 ,  A61K39/42 ,  A61K39/00

Abstract: The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.

公开(公告)号：US12091463B2

公开(公告)日：2024-09-17

申请号：US16636250

申请日：2018-08-08

Applicant: Orionis Biosciences Inc. ,  Orionis Biosciences BV

Inventor： Nikolai Kley ,  Jan Tavernier ,  Lennart Zabeau ,  Erik Depla

IPC: C07K16/18 ,  A61K38/17 ,  A61K38/21 ,  A61K39/395 ,  A61K39/40 ,  A61K39/42 ,  A61P25/00 ,  C07K14/47 ,  C07K16/00 ,  C07K16/28

CPC classification number: C07K16/2851 ,  A61K38/17 ,  A61K38/212 ,  A61K38/215 ,  A61K39/395 ,  A61K39/40 ,  A61K39/42 ,  A61P25/00 ,  C07K14/4713 ,  C07K16/00 ,  C07K16/18 ,  C07K2319/00 ,  C07K16/00 ,  A61K38/212 ,  A61K38/215

Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.

公开(公告)号：US12083190B2

公开(公告)日：2024-09-10

申请号：US17746844

申请日：2022-05-17

Applicant: CureVac SE

Inventor： Margit Schnee ,  Thomas Kramps ,  Lothar Stitz ,  Benjamin Petsch

IPC: A61K39/12 ,  A61K9/00 ,  A61K39/205 ,  A61K39/42 ,  A61K48/00 ,  C07K14/005 ,  C07K16/10 ,  C12N7/00 ,  A61K39/00

CPC classification number: A61K48/0075 ,  A61K9/0021 ,  A61K39/12 ,  A61K39/205 ,  A61K39/42 ,  C07K14/005 ,  C07K16/10 ,  C12N7/00 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/552 ,  C12N2760/20134

Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof.
Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.

公开(公告)号：US12077573B2

公开(公告)日：2024-09-03

申请号：US18335869

申请日：2023-06-15

Applicant: The University of Chicago

Inventor： Patrick Wilson ,  Yaoqing Chen ,  Haley L. Dugan

IPC: C07K16/10 ,  A61K39/42 ,  A61K45/06 ,  A61P31/16 ,  A61K39/00

CPC classification number: C07K16/1018 ,  A61K39/42 ,  A61K45/06 ,  A61P31/16 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein are anti-neuraminidase agents useful for neutralization of influenza virus infection, and methods of use and manufacture thereof. In particular, compositions comprising anti-neuraminidase agents (e.g., antibodies) that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.

公开(公告)号：US20240226291A9

公开(公告)日：2024-07-11

申请号：US18477785

申请日：2023-09-29

Applicant: The Trustees of the University of Pennsylvania ,  Inovio Pharmaceuticals, Inc. ,  The Wistar Institute of Anatomy and Biology

Inventor： David Weiner ,  Karuppiah Muthumani ,  Jian Yan

IPC: A61K39/42 ,  A61K39/12 ,  A61P31/14 ,  C07K14/18 ,  C07K16/10

CPC classification number: A61K39/42 ,  A61K39/12 ,  A61P31/14 ,  C07K14/18 ,  C07K16/10 ,  C07K16/1081 ,  A61K2039/53

Abstract: Disclosed herein is a composition comprising a recombinant nucleic acid sequence that encodes an antibody to a Zika viral antigen, and functional fragments thereof. The invention also relates to a composition comprising the combination of a first composition that elicits an immune response in a mammal against zika virus and a second composition comprising a recombinant nucleic acid sequence encoding an antibody, a fragment thereof, a variant thereof, or a combination thereof. In some instances, the nucleic acid molecule comprises a nucleotide sequence encoding an anti-ZIKV-Envelope (anti-ZIKV E) Protein antibody.

公开(公告)号：US11987617B2

公开(公告)日：2024-05-21

申请号：US18365869

申请日：2023-08-04

Applicant: Gilead Sciences, Inc.

Inventor： Mini Balakrishnan ,  Brian A. Carr ,  Magdeleine S. Hung ,  Manu Kanwar ,  Doug Rehder ,  Matthew Robert Schenauer ,  Loredana Serafini ,  Nathan D. Thomsen

IPC: A61K39/42 ,  A61P31/18 ,  C07K16/10 ,  A61K45/06

CPC classification number: C07K16/1063 ,  A61P31/18 ,  A61K45/06 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76

Abstract: Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.

公开(公告)号：US20240075139A1

公开(公告)日：2024-03-07

申请号：US17766705

申请日：2020-10-07

Applicant: Universität zu Köln ,  Yeda Research and Development Co., Ltd. Weizmann Institute of Science

Inventor： Florian Klein ,  Matthias Zehner ,  Stefanie Ehrhardt ,  Ron Diskin

IPC: A61K39/42 ,  A61P37/04

CPC classification number: A61K39/42 ,  A61P37/04 ,  A61K2039/55

Abstract: The present invention relates to a method for obtaining monoclonal human antibodies directed against an infectious pathogen, monoclonal human antibodies or binding fragments thereof which are directed against an infectious pathogen as obtained by the method of the invention, a pharmaceutical composition comprising such monoclonal human antibodies, a kit comprising such antibodies, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament and in the treatment or prevention of a disease caused by the infectious pathogen.